A novel translation re-initiation mechanism for the p63 gene revealed by amino-terminal truncating mutations in Rapp-Hodgkin/Hay-Wells-like syndromes

Tuula Rinne1, Suzanne E. Clements3, Evert Lamme2, Pascal H.G. Duijf4, Emine Bolat1, Rowdy Meijer1, Hans Scheffer1, Elisabeth Rosser5, Tiong Yang Tan6, John A. McGrath3, Joost Schalkwijk2, Han G. Brunner1, Huiqing Zhou1 and Hans van Bokhoven1,*

1Department of Human Genetics and 2Laboratory of Skin Biology and Experimental Dermatology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands, 3St John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, The Guy’s King’s College and St Thomas’ Hospitals’ School of Medicine, London SE1 9RT, UK, 4Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, NY 10065, USA, 5Department of Clinical Genetics, Great Ormond Street Hospital for Children, London WC1N 3EH, UK and 6Genetic Health Services Victoria, Murdoch Children’s Research Institute, Royal Children’s Hospital, Victoria 3052, Australia

Received January 28, 2008; Revised and Accepted March 19, 2008

Missense mutations in the 3’ end of the p63 gene are associated with either RHS (Rapp-Hodgkin syndrome) or AEC (Ankyloblepharon Ectodermal defects Cleft lip/palate) syndrome. These mutations give rise to mutant p63α protein isoforms with dominant effects towards their wild-type counterparts. Here we report four RHS/AEC-like patients with mutations (p.Gln9fsX23, p.Gln11X, p.Gln16X), that introduce premature termination codons in the N-terminal part of the p63 protein. These mutations appear to be incompatible with the current paradigms of dominant-negative/gain-of-function outcomes for other p63 mutations. Moreover it is difficult to envisage how the remaining small N-terminal polypeptide contributes to a dominant disease mechanism. Primary keratinocytes from a patient containing the p.Gln11X mutation revealed a normal and aberrant p63-related protein that was just slightly smaller than the wild-type p63. We show that the smaller p63 protein is produced by translation re-initiation at the next downstream methionine, causing truncation of a non-canonical transactivation domain in the ΔN-specific isoforms. Interestingly, this new ΔΔNp63 isoform is also present in the wild-type keratinocytes albeit in small amounts compared with the p.Gln11X patient. These data establish that the p.Gln11X-mutation does not represent a null-allele leading to haploinsufficiency, but instead gives rise to a truncated ΔNp63 protein with dominant effects. Given the nature of other RHS/AEC-like syndrome mutations, we conclude that these mutations affect only the ΔNp63α isoform and that this disruption is fundamental to explaining the clinical characteristics of these particular ectodermal dysplasia syndromes.

INTRODUCTION

p53 Protein and its evolutionary predecessors p63 and p73 constitute a family of key transcriptional regulators in cell growth, differentiation and apoptosis. While p53 is a major player in tumorigenesis, p63 and p73 appear to have pivotal roles in embryonic development. p73-Deficient mice have neurological and inflammatory problems, whereas

*To whom correspondence should be addressed at: Department of Human Genetics 588, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Tel: +31 243616696; Fax: +31 243668752; Email: h.vanbokhoven@antrg.umcn.nl

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
The p63 gene consists of 16 exons located on chromosome 3q28. At least six different protein isoforms can be produced, due to two different promoter sites and three different splicing routes. The amino-terminal ends are called TA and DΔN, and at the carboxy-terminal end, α, β and γ termini can be synthesized (Fig. 1). Several functional domains have been identified. The central DNA-binding domain and isomerization domain are present in all p63 isoforms. The canonical transcription activation (TA) domain is located at the amino-terminal end of the TAp63 isoforms. The ΔN-isoforms also contain an amino-terminal transactivation domain, denoted TA2 (10,11). The carboxy-terminal end has two additional domains: the sterile-alpha-motif (SAM) domain and a transactivation inhibitory (TI) domain, which are both only present in the largest carboxy-terminal variant, p63α (12).

Heterozygous mutations in the human p63 gene cause developmental disorders, characterized by various combinations of ectodermal dysplasia (ED), limb malformations and orofacial clefting (13,14). To date, seven different disorders have been linked to mutations in the p63 gene (15). These conditions may have overlapping phenotypic features, but some genotype-phenotype correlations have emerged (16). EEC syndrome (Ectrodactyly Ectodermal dysplasia and cleft lip/palate) (OMIM 106150) has been linked to several important signaling pathways, such as epidermal growth factor (EGF), fibroblast growth factor (FGF), bone morphogenetic protein (BMP), and Notch, Wnt (wingless-type) and Hedgehog (4–9).

In this article we describe four patients from three families with phenotypes consistent with RHS/AEC syndromes that result from atypical nonsense mutations (p.Gln11X, p.Gln16X) or a deletion mutation (p.Gln9fsX23), all of which lead to a premature termination codon (PTC) in the early amino-terminal end of the ΔNp63-isoforms. These mutations are predicted to give rise to a null allele, which contradicts the accepted disease mechanism of other mutations. Surprisingly, in keratinocytes from the patient with the p.Gln11X mutation we were able to detect normal p63 RNA levels of both alleles, but also an additional smaller protein product. Using molecular studies we could demonstrate that the smaller p63 protein was produced by translational re-initiation at the next methionine after the PTC. This causes a deletion of 25 amino acids in the ΔNp63-isoforms, abrogating the TA2 domain, and thus suggesting a crucial role for this part of p63 in the pathogenesis of RHS/AEC syndromes.

RESULTS
Identification of atypical mutations predicting N-terminal premature stop codons

We identified four patients in three families with a clinical presentation reminiscent of AEC/RHS-like ED syndrome (for details see Materials and Methods). Direct sequencing of all 16 exons of the p63 gene revealed three different heterozygous nucleotide changes in affected individuals. In family 1, both mother and daughter have a nucleotide change c.31C>T (Fig. 2A) (accession number AF075431) in the first coding exon, the alternative exon 3', that is present only in the ΔNp63 isoform. The c.31C>T mutation changes glutamine to a stop codon at amino acid position 11, creating a PTC in all ΔNp63 isoforms. In family 3, a deletion of one nucleotide (c.26delA) was identified (Fig. 2B), also located in the alternative exon 3' of ΔNp63 isoforms. This causes a frameshift and a PTC 41 nt downstream from the deletion (Fig. 2E). In family 2, a nucleotide change c.46C>T was detected in exon 4 (Fig. 2C). This mutation causes a change of glutamine to a stop codon at amino acid position 16 in the ΔNp63 isoforms and at position 71 in TAp63 isoforms. The genomic change
c.46C>T (or c.211C>T in TAp63 accession number AF075430) indicates a PTC in both ΔN and ΔTAp63 isoforms. These three mutations were not identified in DNA from any of the unaffected family members nor in 300 control DNAs, indicating that they are all pathogenic, resulting in RHS/AEC-like syndromes.

Harmful and deleterious transcripts with a PTC are usually degraded through nonsense-mediated decay (NMD). In addition, a translation start prediction program estimated that the nucleotide change c.31C>T was also present in the keratinocyte RNA pool. The presence of both alleles (Fig. 2D) argues against NMD.

To provide further support for the translation re-initiation hypothesis, we performed transfection studies in p63 negative Saos-2 cells. We performed transient transfections with a full-length ΔNp63α cDNA under a constitutive CMV promoter, pCDNA3 CMV_ΔNp63α. After transfections, the expression of each construct was confirmed by immunofluorescent labeling (data not shown). Protein lysate of each transfection was analyzed by western blotting. Firstly, we mutated the second methionine at position 26 to isoleucine to investigate whether this methionine is involved in translation initiation of the smaller ΔNp63α fragment. Wild-type ΔNp63α is
expressed in undifferentiated cultured keratinocytes. Dg gives similar results than is not degraded by NMD as expected. qPCR with p63 is very similar to the control, indicating that RNA containing the mutation suggests that methionine 26 is used to initiate the translation protein variants were detected (Fig. 4C). This strongly demonstrated a molecular size reduction (ΔNp63α 3 kDa) after introduction of the p.Gln11X, p.Gln16X or p.Gln9fsX23 mutation into cells and p.Gln16X_Met26Ile (lane 6) and p.Gln9fsX23_p.Met26Ile (lane 8) no p63α protein product is detected at all. This experiment clearly demonstrates that all three pathogenic mutations cause translational re-initiation at methionine 26.

Transcriptionally inactive ΔΔNp63α

The protein analysis showed that the p.Gln11X mutation causes an amino-terminal deletion of 25 amino acids. To study the transactivational activity of the ΔNp63 amino-terminus, we tested a series of truncation mutations in the ΔNp63α isoform (Δ14, Δ26, Δ43, Δ61, Δ79) for transactivation activity (Fig. 5A). Full-length ΔNp63α was able to activate an optimized p53 promoter nearly 6-fold more than the empty vector. In contrast, truncation of the first 14 amino acids completely abolished the activation (Fig. 5B). The same inactivating effect was detected for all other truncation mutations. Thus, 14 unique amino acids at the ΔN-terminus of p63 constitute a functional domain, which has transactivational

Figure 3. ΔNp63α levels in cultured keratinocytes from a Rapp-Hodgkin syndrome patient. ΔNp63 and p63α expression levels are investigated in undifferentiated keratinocytes by qPCR. The control (dark gray bar) is a pool of five control samples and the RHS patient sample (light gray bar) is from the mother of family 1 containing the p.Gln11X mutation. Housekeeping genes ACTB, GAPDH and hARP were used in normalization. qPCR with two ΔNp63 specific primer sets (A and B) show that ΔNp63 expression in RHS is very similar to the control, indicating that RNA containing the mutation is not degraded by NMD as expected. qPCR with p63α specific primer set gives similar results than ΔNp63 specific primer sets (C). Furthermore, similar Ct-values (data not shown) indicated ΔNp63α to be the only isoform expressed in undifferentiated cultured keratinocytes.

Figure 4. An additional ΔNp63α protein product in Rapp-Hodgkin syndrome patient is caused by translational re-initiation at methionine 26. (A) The lysate of cultured keratinocytes was run on NuPAGE® Bis–Tris Pre Cast Gels System, p63α-specific antibody H-129 [Santa Cruz] was used to detect the signal on nitrocellulose membrane. This experiment demonstrates two ΔNp63α protein variants in cultured keratinocytes. In control samples (lanes 1 and 2), the smaller ΔNp63α variant is present in small quantities. However, in the Rapp-Hodgkin syndrome sample (lane 3) the ratio is about one to one. α-tubulin (Abcam) is used as a loading control. (B) The second putative initiation site in ΔNp63, methionine 26, was mutated to isoleucine in a wild-type expression vector and transiently transfected into p63 negative Saos-2 cells, and harvested 30–48 h after transfection. The cell lysates were run on 8% SDS-Polyacrylamide gel and blotted to a nitrocellulose membrane. This was incubated with p63α-specific antibody H129 [Santa Cruz]. Mock (lane 1) is negative. When transfecting the wild-type ΔNp63α (lane 2) two p63 products are clearly present. However, when transfecting the mutation construct (Met26 is mutated to isoleucine), the lower product is missing (lane 3). This indicates that methionine at position 26 can initiate the transactivation. (C) N-terminal RHS and AEC mutations were also introduced to the expression vector along with the vector containing the Met26Ile mutation. These constructs were transfected into the Saos-2 cells and prepared as described above. Lane 1 contains empty vector pcDNA3. Wild-type ΔNp63α (lane 2) produces the double band similar to 4B. However, when transfecting the pathogenic mutations p.Gln11X (lane 3), p.Gln16X (lane 5) and p.Gln9fsX23 (lane 7) the upper product is completely absent. When a combination of pathogenic mutation plus a Met26Ile mutation is present (p.Gln11X_Met26Ile (lane 4), p.Gln16X_Met26Ile (lane 6) and p.Gln9fsX23_p.Met26Ile (lane 8)) no p63α protein product is detected at all. This experiment clearly demonstrates that all three pathogenic mutations cause translational re-initiation at methionine 26.
activity. This is in accordance with previous studies on other promoters (10,11,40).

Because ∆Np63α is the predominant isoform in keratinocytes, we set out to test the ability of the p.Gln9fsX23, p.Gln11X and p.Gln16X mutants to regulate downstream target genes. Keratin-14 (K14) was recently reported to be a natural target gene of p63, which is upregulated by ∆Np63α (40–42). A transactivation assay of p63-negative Saos-2 cells transfected with either ∆Np63α wild-type, mutant or a combination of these constructs, together with a K14-luciferase-reporter construct, revealed that wild-type ∆Np63α was able to activate the K14 promoter 2.5 times more than the empty vector. This is in contrast to all ∆Np63α mutant constructs (p.Gln9fsX23, p.Gln11X and p.Gln16X), which were inactive and behaved similar to empty vectors (Fig. 5C). Co-transfections of single mutation in combination with ∆Np63α wild-type vector showed no increased K14-promoter activation (Fig. 5C), indicating a dominant effect of these mutations against the wild-type. Next we investigated whether the mechanism of action of the mutant ∆Np63α protein might be dose dependent. To that end, we co-transfected Saos-2 cells with the wild-type and mutant constructs in a 5:1, 1:1 and 1:5 ratio (Fig. 5D). The 5:1 ratio of wild-type and p.Gln11X mutant was able to activate the K14 promoter 2.5 times, whereas none of the ∆Np63α mutants is able to activate the promoter at all. Neither co-transfection of wild-type and mutant are able to activate K14 promoter, indicating a dominant negative effect for the mutants. (D) Saos-2 cells were transfected with wild-type and p.Gln11X ∆Np63α constructs in different ratios and K14 promoter activity was measured. 5:1 ratio of ∆Np63α wild-type and p.Gln11X can activate K14 promoter similar to ∆Np63α wild-type construct, however, when using 1:1 or 1:5 ratio, which mimics RHS p.Gln11X construct. This supports the hypothesis that ∆Np63α is a dose-dependent regulator of ∆Np63α. (E) Finally, Saos-2 cells were transfected with TAp63γ and ∆Np63α isoforms. Wild-type TAp63γ can activate the p53-promoter 34 times when comparing with empty vector, whereas ∆Np63α cannot activate the promoter at all. Instead, ∆Np63α wild-type inhibits the activity of TAp63γ in a co-transfection assay. This dominant negative effect against the TAp63γ is also detected in the RHS p.Gln11X ∆Np63α, indicating that the mutated molecule is able to bind to the promoter.
DISCUSSION

Until now, mutations causing RHS and AEC syndrome have only been described in exons 13 and 14, which encode the SAM and TI domains of the p63α-protein. Here we report three RHS/AEC families without any changes in these exons, but with novel pathogenic mutations in the amino-terminus of ΔNp63: p.Gln9fsX23 and p.Gln11X (in the alternative exon 3') and p.Gln16X (in exon 4). The first two are present in only the ΔNp63 isoforms, whereas the latter is present in both ΔNp63 and TAp63 isoforms. All these mutations lead to PTCs soon after the first translation initiation codon. Despite this, these mutant alleles still produce a p63-related protein by re-initiation of translation at the next ATG codon. Recently, similar translation re-initiation processes have been reported in genes causing other human inherited diseases, such as breast cancer, Menkes disease and Incontinentia pigmenti (36–39). Nevertheless, this is the first time that altered N-terminus and translation re-initiation has been linked to RHS and AEC syndromes.

The mutations reported here are not associated with severe skin phenotype. Absence of skin defects is also observed in 60% RHS and 20% of AEC syndrome patients (28). Since we have studied only four patients, it cannot be concluded whether the lack of severe skin defects is related to the position of the mutations or just a reflection of the normal clinical variety in RHS/AEC. The three novel mutations we have reported are of particular interest, as they differ completely from the previously identified mutations in Rapp-Hodgkin and AEC syndromes. The 23 pathogenic mutations reported so far in p63 in these disorders are missense mutations, deletions or insertions clustered in the α-terminus of p63, changing the composition of the SAM and TI domains (15–29). However, our new findings, based on the sites of the p.Gln11X, p.Gln16X and p.Gln9fsX23 mutations, imply that ΔNp63α is the critical isoform causing RHS/AEC syndrome. One of the new mutations we report (p.Gln16X/p.Gln71X) also affects the TA-isoform, although since ΔNp63α is the only p63 isoform (99%) expressed in epithelial tissues, the relevance of TA-isoform disruption remains obscure (8,40). Moreover, the phenotype of the patient carrying the p.Gln16X/p.Gln71X mutation is not significantly different from that of the patients with the other mutations in families 1 and 3. This strongly indicates that either an aberrant ΔN- or α-terminus of p63 cause a condition which is characterized by ED and orofacial clefting, but not developmental limb problems.

It has been shown previously that ΔNp63α can function both as an activator and a repressor of transcription (10,40,43–45). We tested transactivation activity of p.Gln9fsX23, p.Gln11X and p.Gln16X in a transactivation assay on the K14 promoter, on which ΔNp63α acts as an activator of transcription. Mutant constructs are unable to activate the K14 promoter (Fig. 5C), indicating that the first 25 amino acids are crucial for the activation. This is in accordance with the results of transactivation assays in this paper (Fig. 5B), in which deletion mutants affect the N-terminal TA2 domain. In addition, in previous assays the N-terminal deletion abrogates the activity to transactivate p53 target genes and induce cell cycle arrest and apoptosis (10,11). Our TAp63γ co-transfection assay show that the p.Gln11X mutant can inhibit TAp63γ-mediated transactivation (Fig. 5E), indicating that this mutant is able to bind to DNA and form heteromers with other p63 isoforms. Previously, we have demonstrated that the SAM domain mutant proteins have lost their ability to form p63-protein complexes and their ability to bind to DNA (18). Apparently, the ΔN-mutant proteins have retained these properties. It is unclear whether these properties have an effect on the phenotype since they are highly similar, except perhaps for the skin phenotype, which is not severe in the patients with N-terminal mutation. In addition, the ΔNp63α co-transfection assay shows that all these three mutants can inhibit ΔNp63α wild-type transactivation (Fig. 5C), suggesting that these mutations have a dominant negative effect.

The first 25 amino acids in the ΔNp63α are crucial for the correct function of the ΔNp63 isoforms. The shorter ΔNp63α variant was also detected in wild-type keratinocytes as well as in ΔNp63α-transfected Saos-2 cells (Fig. 4). In keratinocytes, this new isoform appears to be more abundant than any other p63 isoform (TA, β, γ) except ΔNp63α. This indicates that the p63 gene encodes more protein isoforms than the six that have been recognized to date (Fig. 1). Therefore, this p63 variant appears to be a novel translational variant and apparently not deleterious for the cells. We hypothesize that in keratinocytes the ΔΔNp63α isoform has a regulatory function, which is imbalanced in patients because of the increased amount of ΔNp63α. Our dose-dependent assay of ΔNp63α and ΔΔNp63α on K14 promoter also showed that elevated amount of ΔΔNp63α represses the ΔNp63α activation (Fig. 5D). Thus, the disturbed ratio between the full-length and shorter p63 variant might be relevant for causing the disease phenotype. Since AEC/RHS is a dominantly inherited disease, we propose a dominant-negative effect of the ΔΔNp63α variant against wild-type ΔNp63α in either a dimer or tetramer structure. Once the mutated and wild-type isoform form a functional protein complex, the ΔΔNp63α isoform may alter the function of this complex, working as a repressor or an activator.

Both ΔN- and α-terminal mutations can lead to a highly similar clinical phenotype, although the molecular mechanisms involved in the pathogenesis are as yet unknown. The TI-domain of the α-terminus intra-molecularly binds to the N-terminal TA-domain, even though this has not been reported for the ΔN-terminus of ΔNp63α (12). It appears however, that both types of mutations have an effect on transcription regulation by ΔNp63α. Here we have shown that deletions of ΔNp63 result in reduced transactivation activity by ΔNp63α on p53 and p63 promoters. Previously we have shown that SAM-domain mutants ablate the transactivational inhibitory effects of ΔNp63α towards transactivation by p53 and TAp63γ (18). Consequently, both N-terminal and SAM-domain mutations associated with RHS/AEC syndrome appear to affect transactivation activity by ΔNp63α isoforms. A systematic screening of the effects of constructs with N- and C-terminal mutations on a panel of natural p63 target genes and in a relevant cell type, such as in keratinocytes, may give further insight into the precise disease mechanism in RHS/AEC syndrome. From the present study, we conclude that the generation of an N-terminally truncated ΔNp63α
protein is responsible for causing a Rapp-Hodgkin and AEC syndrome-like phenotype.

MATERIAL AND METHODS

Clinical study

The index patient of family 1 is a 6-year-old girl, who has a unilateral cleft lip and palate. She has coarse dry blond hair and fair skin and there is scaling on the forehead, around the nipples and on the buttocks. She is anhidrotic. At birth she had a systolic murmur, but on ultrasound was found to have a normal cardiac anatomy and the murmur appeared to be innocent. The index patient’s mother also has ED: her hair has a coarse texture and a spiky appearance. Her skin is dry, and she has hypodontia of her primary teeth and her fingernails are dystrophic. She has anhidrosis on her trunk and limbs but is able to sweat normally from her palms and soles. In addition, she has had frequent urinary tract infections. Unlike her daughter she has secondary hearing loss due to a malformation of the external ear canal. She also had a history of a malignant melanoma, which had been excised from her right hand.

The index patient of family 2 is a 2-year-old boy, who was born to non-consanguineous parents of Greek-Australian descent. He has a unilateral cleft of the soft palate and left-sided ankyloblepharon filiforme. He has sparse eyebrows and eyelashes in infancy, but no alopecia or dry skin. He has small nails, which are not dystrophic. He also has hypoplastic alae nasi. There are no dental anomalies or delayed dental eruption.

The patient in family 3 is a 13-year-old girl. She was born with an absent hard palate in her mouth, ankyloblepharon filiforme and an atrial septal defect. As an infant she was prone to infections, but this later improved. She has upslanting palpebral fissures, a long nose and a small mouth with a thin upper lip. She has sparse eyelashes, but extremely thick and bushy hair, which is easy to brush. Her hands, feet and nails are all normal.

Mutation analysis

Blood samples and skin samples used in this study were obtained after informed consent was obtained. Genomic DNA was extracted from peripheral blood samples by a standard salting-out method. All 16 exons of the p63 gene were amplified and sequenced in both directions. Primers, which were used to amplify the alternative exon 3’ and exon 4 are illustrated in Table 1A.

Cell culture

A skin biopsy (4 mm diameter) was taken from the back of the index patient’s mother. The skin was collected in RPMI [Gibco] medium with Gentamycin (1:1000) [Gibco], Amphoterin (1:100) [Gibco] and Penicillin/Streptomycin [Gibco]. The biopsy was then trypsinized in 0.25% Trypsin–PBS [Brunschwig] overnight at 4°C following which the upper epidermal layer was separated from the biopsy with tweezers and the dermal surface was scratched smoothly to release the keratinocytes. Serum was added to stop the trypsin activity. Next the solution containing the dermal and epidermal components was vortexed at low speed for 1 min. The dermal parts were removed and the epidermal cells were added on to irradiated 3T3-J2 cells. Cells were cultured in Green’s medium: DMEM [Gibco], Ham’s F12 [Gibco] (2:1) supplemented with 10% fetal bovine serum [Hyclone], 4 mM L-Glutamine [ICN Biomedicals], 100 U/ml penicillin [Gibco], 100 μg/ml streptomycin [Gibco], 25 μg/ml adenine [Calbiochem], 5 μg/ml insulin [Sigma], 0.4 μg/ml hydrocortisone [Calbiochem], 1.4 ng/ml triiodothyronine [Sigma], 0.1 nM Cholera toxin [Sigma]. EGF (10 ng/ml) [Sigma] was added to the medium 3 days after starting the keratinocyte culture. The medium was refreshed every second day until the culture reached 80–90% confluence. The primary keratinocyte stocks were stored in liquid nitrogen.

Mouse fibroblast cell line 3T3-J2 was used as a feeder layer for the keratinocytes in Green’s medium. Pure 3T3-J2 cells were cultured in DMEM w/o pyruvate [Gibco] containing 10% calf serum supplemented by iron [Hyclone] and 100 U/ml penicillin [Gibco] and 100 μg/ml streptomycin [Gibco]. 3T3 cells were irradiated at 3500 cGy about 20 h before adding keratinocytes.

Keratinocytes were cultured at 37°C in 5% CO2 in Keratinocyte growth medium (KGM). This medium consists of Keratinocyte Basal Medium, 0.15 mM Ca2+ [Cambrex], supplemented with 0.1 mM ethanolamine [Sigma], 0.1 mM phosphoethanolamine [Sigma], bovine pituitary extract (0.4%) [Bio Whittaker], 10 ng/ml EGF [Sigma], 5 μg/ml insulin [Sigma], 0.5 μg/ml hydrocortisone [Calbiochem], 100U/ml penicillin [Gibco] and 100 μg/ml streptomycin [Gibco]. The medium was changed every second day until the culture reached confluent state.

Transfection conditions

Human osteoblast cell line Saos-2 was used for transient transfections. Saos-2 cells were cultured in DMEM [Gibco] supplemented by 10% fetal calf serum [Sigma], 1% natrium-pyruvate [Gibco], 1% Glutamax-1 [Gibco] and 100 U/ml penicillin [Gibco] and 100 μg/ml streptomycin [Gibco]. Approximately 1.5 × 105 Saos-2 cells were seeded in one well of a 6-well tissue culture plate. Effectene transfection reagent [Qiagen] was used to transfect the pcDNA3, pcDNA3_Mm ΔNp63α (43) wild-type and its mutant versions p.Gln11X, p.Gln16X, p.Gln9fsX23, Met26Ile and double mutant p.Gln11X_Met26Ile, p.Gln16X_Met26Ile and p.Gln9fsX23_Met26Ile constructs into Saos-2 cells. The same method was used for co-transfections, where either pcDNA3_Mm ΔNp63α wild-type was transfected together with each single mutant (p.Gln11X, p.Gln16X, p.Gln9fsX23) ΔNp63α construct or pcDNA3_TAp63α wild-type was transfected together with wild-type or mutant (p.Gln11X) pcDNA3_Mm ΔNp63α construct. The cells were collected 30–48 h after transfection.

For transfections of the ΔNp63 truncation mutations (Δ14, Δ26, Δ43, Δ61, Δ79), Saos-2 cells were plated on 18 mm round glass coverslips and a total of 2 µg plasmid DNA was transfected using a calcium phosphate precipitation protocol (46).
Luciferase assays
Subconfluent Saos-2 cells were transfected as described above at a 1:2 ratio between the reporter construct (firefly luciferase under control of K14 promoter) (kind gift of Dr B. Andersen and Dr E. Candi) and the wild-type or mutant (p.Gln11X, p.Gln16X, p.Gln9fsX23) pcDNA3_ΔNp63x or a combination of wild-type and mutant vector. In addition, 50 ng of Renilla luciferase construct was co-transfected in each transfection to normalize for transfection efficiency. After 30 h the transfection luciferase activities were measured using a Dual Luciferase Reporter Assay System [Promega] according to the manufacturer’s instructions. The level of activation was calculated in comparison with transfections with an empty pcDNA3 wt or mutant. In addition, 5 ng of Renilla luciferase construct was transfected in each transfection to normalize for transfection efficiency. After 30 h the transfection luciferase activities were measured using a Dual Luciferase Reporter Assay System [Promega] according to the manufacturer’s instructions. The level of activation was calculated in comparison with transfections with an empty pcDNA3 vector. Transfections for the TAp63γ co-transfection assay were carried out as described above at a 1:3 ratio between the reporter construct (β-galactosidase reporter under p53 promoter) and expression construct (pcDNA3_Mm_TAp63γ wt-type, pcDNA3_ΔNp63x wild-type or p.Gln11X mutant construct, or in co-transfections TAp63γ in combination with ΔNp63x wt or mutant). In addition, 5 ng of Renilla luciferase construct was transfected in each transfection to normalize for transfection efficiency. After 30 h the transfection β-galactosidase and luciferase activities were measured using a Luminescent beta-galactosidase detection kit II [Clontech] and a Renilla Luciferase Reporter Assay System [Promega] according to the manufacturer’s instructions. The level of activation was calculated in comparison with transfections with an empty pcDNA3 vector. Transactivation assays of the truncation mutations were carried out as described previously (43).

Mutagenesis
Pathogenic mutations of interest were introduced into the pcDNA3_ΔNp63x vector by using QuickChange Site-Directed Mutagenesis kit [Stratagene] according to the manufacturer’s instructions. The p.Gln11X, p.Gln16X, p.Gln9fsX23 and p.Met26Ile mutations were introduced in this vector. The p.Gln11X, p.Gln16X and p.Gln9fsX23 mutations were also introduced into pcDNA3_ΔNp63x_Met26Ile mutation construct to create double mutations. Mutagenesis primers are shown in Table 1D. The correct sequence of each clone was determined by direct sequencing of the entire cDNA insert. N-terminal deletion mutations were introduced into pcDNA3_Mm_ΔNp63γy vector by using ExSite PCR-based site-directed mutagenesis procedure [Stratagene] according to the manufacturer’s instructions. The sequences encoding amino acids 2–14, 2–26, 2–43, 2–61 and 2–79 (amino acid numbers referring to ΔNp63 protein) were removed using oligonucleotides described in Table 1D. The obtained clones were screened for the presence of the respective deletions by direct sequencing using primers flanking the deletions.

Sample preparation and immunoblotting
Transfected Saos-2 cells and keratinocytes were grown in PBS and centrifuged at 4°C at 3000 RPM for 10 min. The pellet was lysed in lysis buffer containing: 50 mM Tris-HCl pH 7.8, 10% glycerol [Invitrogen], 0.5% Nonidet-P40 [Brunschwig], and 5 mM Ethylene glycol-bis-tetraacetic acid (EGTA) [Fluka], and freshly added 10 mM β-mercaptoethanol [Sigma], 0.5 mM Phenylmethanesulfonyl fluoride [Fluka], 1 μg/ml Pepstatin A [Fluka] and 1 x protease inhibitory cocktail [Roche], for 20 min on ice. Immunoblotting was performed using the NuPAGE® Bis-Tris Pre Cast Gel System [Invitrogen] following the manufacturer’s instructions. Samples were run on a 4–12% NuPAGE® Bis-Tris gel in MOPS buffer [Invitrogen], p30-specific polyclonal antibody H-129 (1:500) [Santa Gruz] was used to detect p63 and a mouse monoclonal α-Tubulin antibody DM1A (1:5000) [Abcam] was used as a loading control. Alexa-680 goat-anti-rabbit secondary antibody [Molecular Probes] and IrDye-800 goat-anti-mouse secondary antibody [Rockland]
were both used in 1:5000 dilution. The signal detection was performed by Odyssey scanner [Licor].

RNA isolation
Keratinocytes were cultured in KGM and harvested either at confluent state or after 48 h differentiation. Total RNA isolation was performed using the RNeasy mini kit [Qiagen] according to the manufacturer’s instructions. RNA was treated with DNase I while bound to the RNeasy column to remove residual traces of genomic DNA [Qiagen]. The integrity of the RNA was assessed on an agarose gel, and the concentration and purity were determined with a ND-1000 spectrophotometer [NanoDrop].

Reverse transcriptase PCR
Two µg of total RNA was transcribed into cDNA as described earlier (47). cDNA was amplified with a forward primer specific to alternative exon 3' of p63 gene and a reverse primer specific to exon 4 with a total number of 35 cycles. Primer sequences are in Table 1B. The RT-PCR product was electrophoresed in an agarose gel and purified using the Qiagen kit [Qiagen]. This cDNA product was sequenced with reverse primer by using a 3730 DNA analyzer from Applied Biosystems.

Quantitative PCR
qPCR was performed on the MyiQ single-color real-time detection system (Biorad) by using iQ SYBR® Green Supermix [Biorad] according to the manufacturer’s protocol. All primer pairs were designed such that they cover either separate exons or that one is spanning an exon-exon boundary. All primers were validated in triplicate by use of serial cDNA dilutions, and were confirmed for 100 ± 5% efficiency. Differences in the expression of a gene of interest between two samples were calculated by 2ΔΔCT method (48,49). To normalize the amount of cDNA we used three housekeeping genes: beta-actin (ACTB), hARP (human acidic ribosomal protein) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase protein). All samples were used in duplicate and housekeeping genes were run on the same plate in the iQ-apparatus as the gene of interest. Primer sequences are provided in Table 1C.

WEB RESOURCES
Accession numbers and URLs for data presented in this article are as follows: GenBank, http://ncbi.nlm.nih.gov/GenBank [Accession numbers NT_005612.15, AF_075430, AF_075431, NM_000526, NM_001101, NM_001002 and NM_002046 (these are in Table 1), AAG45610, AAP87985, CAC37099, BAB20631, AAK15622, AAN03691 (these are in multiple sequence alignment in Fig. 5A).


ACKNOWLEDGEMENTS
We thank Dr J. Murray, Dr K. Krahn, Dr S. Daack-Hirsch and Dr A. Mach-Schoenebeck for clinical and diagnostic investigations. We thank Dr B. Andersen and Dr E. Candi for the K14 luciferase construct. And finally we thank all patients for their participation in this study.

Conflict of Interest statement. None declared.

FUNDING
Work in our laboratory is supported by the European Union Sixth Framework programme EpiStem project (LSHB-CT-2005-019067).

REFERENCES


